Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

• Jefferies Healthcare Conference in New York, NY
  Friday, June 9, 2023
  Fireside chat at 8:30 am Eastern Time

• Goldman Sachs 44^th Annual Global Healthcare Conference in Dana Point, CA
  Wednesday, June 14, 2023
  Fireside chat at 4:00 pm Pacific Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmun website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
[email protected]

[ Back To TMCnet.com's Homepage ]